BioShares Biotechnology Valuation

BioShares Biotechnology Clinical Trials -- USA Etf  

USD 30.75  0.51  1.63%

BioShares Biotechnology shows prevailing Real Value of $33.26 per share. The current price of the entity is $30.75. At this time the entity appears to be under valued. Macroaxis approximates value of BioShares Biotechnology from analyzing the entity fundamentals such as Three Year Return of 1.36%, Price to Earning of 39.87times and Price to Sales of 1.99times as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since at some point assets prices and their ongoing real values will blend.
 Time Horizon     30 Days    Login   to change
BioShares Biotechnology Clinical Trials is second largest ETF in price to earning as compared to similar ETFs. It is the top ETF in one year return as compared to similar ETFs reporting about  1.41  of One Year Return per Price to Earning.
Under Valued
January 21, 2018
Market Value
Downside upside
Real Value
Target Price Odds
 Above  Below  
Upside upside
BioShares Biotechnology is not too volatile asset. Calculation of real value of BioShares Biotechnology is based on 1 month time horizon. Increasing BioShares Biotechnology time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.

Net Asset

BioShares Biotechnology Net Asset Analysis
BioShares Biotechnology Clinical Trials is rated below average in net asset as compared to similar ETFs. Total Asset Under Management (AUM) of Health category is currently estimated at about 42.34 Billion. BioShares Biotechnology adds roughly 31.18 Million in net asset claiming only tiny portion of all ETFs under Health category.